ETNB 89bio Inc

Price (delayed)

$8.63

Market cap

$849.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.01

Enterprise value

$658.78M

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is ...

Highlights
ETNB's EPS is up by 24% year-on-year
The equity is up by 15% year-on-year but it is down by 4.8% since the previous quarter
The company's net income has shrunk by 57% YoY and by 16% QoQ
89bio's quick ratio has decreased by 27% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of ETNB
Market
Shares outstanding
98.38M
Market cap
$849.05M
Enterprise value
$658.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$157.49M
EBITDA
-$157.09M
Free cash flow
-$138.83M
Per share
EPS
-$2.01
Free cash flow per share
-$1.45
Book value per share
$5.46
Revenue per share
$0
TBVPS
$6.02
Balance sheet
Total assets
$577.32M
Total liabilities
$66.78M
Debt
$27.3M
Equity
$510.54M
Working capital
$536.54M
Liquidity
Debt to equity
0.05
Current ratio
15.03
Quick ratio
14.7
Net debt/EBITDA
1.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31%
Return on equity
-34.8%
Return on invested capital
-58.3%
Return on capital employed
-29.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ETNB stock price

How has the 89bio stock price performed over time
Intraday
-3.79%
1 week
-0.92%
1 month
-5.79%
1 year
-51.08%
YTD
-22.74%
QTD
-25.86%

Financial performance

How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$179.96M
Net income
-$165.03M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 70% YoY and by 19% QoQ
The company's net income has shrunk by 57% YoY and by 16% QoQ

Growth

What is 89bio's growth rate over time

Valuation

What is 89bio stock price valuation
P/E
N/A
P/B
1.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS is up by 24% year-on-year
The stock's price to book (P/B) is 37% less than its 5-year quarterly average of 2.5 and 34% less than its last 4 quarters average of 2.4
The equity is up by 15% year-on-year but it is down by 4.8% since the previous quarter

Efficiency

How efficient is 89bio business performance
The ROIC has grown by 32% YoY and by 4.4% from the previous quarter
89bio's return on equity has increased by 31% YoY but it has decreased by 12% QoQ
ETNB's return on assets is up by 23% year-on-year but it is down by 12% since the previous quarter

Dividends

What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETNB.

Financial health

How did 89bio financials performed over time
ETNB's total liabilities is up by 38% YoY and by 11% QoQ
ETNB's current ratio is down by 27% year-on-year and by 25% since the previous quarter
89bio's debt is 95% lower than its equity
ETNB's debt to equity is down by 17% YoY
The equity is up by 15% year-on-year but it is down by 4.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.